(R)-Plevitrexed
| Code | Size | Price |
|---|
| TAR-T12635-5mg | 5mg | £850.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Documents
Further Information
Bioactivity:
(R)-Plevitrexed is a less active enantiomer of Plevitrexed. Plevitrexed is an orally active and potent inhibitor of thymidylate synthase (TS).
CAS:
153537-74-7
Formula:
C26H25FN8O4
Molecular Weight:
532.536
Purity:
0.98
SMILES:
Cc1nc2cc(C)c(CN(CC#C)c3ccc(C(=O)N[C@H](CCc4nn[nH]n4)C(O)=O)c(F)c3)cc2c(=O)[nH]1
References
1. Marsham PR, et al. Design?and?synthesis?of?potent?non-polyglutamatable?quinazoline?antifolatethymidylate?synthase?inhibitors. J Med Chem.?1999 Sep 23;42(19):3809-20.
2. Tochowicz A, et al. Development and binding mode assessment of N-[4-[2-propyn-1-yl[(6S)-4,6,7,8-tetrahydro-2-(hydroxymethyl)-4-oxo-3H-cyclopenta[g]quinazolin-6-yl]amino]benzoyl]-l-?-glutamyl-D-glutamic acid (BGC 945), a novel thymidylate synthase inhibitor that targets tumor cells. J Med Chem.?2013?Jul 11;56(13):5446-55.